Edwards Lifesciences EW Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $2.45B-16.7% | $2.94B+9.1% | $2.69B-18.1% | $3.29B+4.5% | $3.15B+2.9% | ||
| $775.7M+17.6% | $659.6M-4.9% | $693.3M-0.5% | $697M+4.2% | $669.2M+9.9% | ||
| $1.12B-0.6% | $1.13B-1.3% | $1.14B-0.1% | $1.14B+2.5% | $1.11B+2.5% | ||
| $6.23B-7.6% | $6.74B+6.0% | $6.36B-3.3% | $6.58B+5.9% | $6.21B-1.2% | ||
| $1.82B+0.6% | $1.81B+3.9% | $1.74B+1.0% | $1.73B+1.7% | $1.7B+0.7% | ||
| $1.82B+2.9% | $1.77B0.0% | $1.77B-0.5% | $1.78B-0.1% | $1.78B+0.1% | ||
| $13.32B-2.7% | $13.7B+3.2% | $13.27B-1.6% | $13.49B+3.6% | $13.02B-0.3% | ||
| $181.1M-20.4% | $227.5M+37.9% | $165M+1.8% | $162.1M-6.0% | $172.4M-12.7% | ||
| $1.41B-22.3% | $1.81B+14.2% | $1.59B+13.0% | $1.4B+0.7% | $1.39B-7.3% | ||
| $598.5M0.0% | $598.3M0.0% | $598.2M0.0% | $598M0.0% | $597.8M0.0% | ||
| $24.1M-31.3% | $35.1M-98.9% | $3.07B+6.4% | $2.88B+1.8% | $2.83B-5.4% | ||
| $14.62B+2.7% | $14.24B+0.6% | $14.15B+2.1% | $13.86B+2.5% | $13.53B+2.7% | ||
| $10.33B-0.1% | $10.34B+1.3% | $10.21B-3.2% | $10.55B+4.1% | $10.13B+1.3% | ||
| $13.32B-2.7% | $13.7B+3.2% | $13.27B-1.6% | $13.49B+3.6% | $13.02B-0.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Edwards Lifesciences's total assets?
- Edwards Lifesciences (EW) holds $13.3B in total assets, up 2.3% year over year.
- How much debt does Edwards Lifesciences have?
- Edwards Lifesciences carries $702.9M in total debt against $10.3B of shareholders' equity, a debt-to-equity ratio of 0.07.
- How much cash does Edwards Lifesciences have?
- Edwards Lifesciences holds $2.4B in cash and equivalents.
- Can Edwards Lifesciences cover its short-term obligations?
- Its current ratio is 4.42 — current assets exceed current liabilities.
- Where does Edwards Lifesciences's balance sheet data come from?
- Every line is extracted from Edwards Lifesciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
